Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* The patient has a diagnosis of Amyotrophic Lateral Sclerosis (according to El Escorial Criteria, WFN, 1998) and the time from diagnosis of ALS is not be longer than 30 months, or the patient has a diagnosis of multiple sclerosis or probable multiple sclerosis (according to McDonald criteria, 2001)~* The patient has a clinical history and clinical relevant symptoms of Pseudobulbar Affect (PBA)~* CNS-LS score at baseline is 13 or greater~Main Exclusion Criteria:~* Patients with myasthenia gravis~* Any personal history of complete heart block, QTc prolongation, or torsades de pointes~* Any family history of congenital QT interval prolongation syndrome~* Patients with known sensitivity to quinidine, dextromethorphan or opiate drugs (codeine, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DM 30 mg/Q 10 mg (Type: EXPERIMENTAL): AVP-923-30/10 Capsules (30 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
- DM 20 mg/ Q 10 mg (Type: EXPERIMENTAL): AVP-923-20/10 Capsules (20 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Capsules once daily for 1 week and then twice daily for an additional 11 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).